Volume 13, Issue 3 (2010)                   mjms 2010, 13(3): 41-52 | Back to browse issues page

XML Persian Abstract Print


1- Department of biology, Science and Research Branch, Islamic Azad University, Tehran-Iran
2- National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran
3- School of Biology, University College of Science, University of Tehran, Tehran, Iran
4- Pilot Biotechnology department, Pasteur Institute of Iran, Tehran, Iran
5- Department of Medical Genetics, Faculty of Medical Sciences, Medical Sciences/ University of Tehran, Tehran, Iran
6- Department of Biology, Science and Research Branch, Islamic Azad University, Tehran-Iran
7- Virology Department, Pasteur Institute of Iran, Tehran, Iran
Abstract:   (5069 Views)
Objective: Prostate cancer is one of the most common cancer in the developed countries. Most of cancer deaths are due to development of metastasis. Hence, prevention of metastasis is critical. Silibinin is a flavonoid component that inhibits cell proliferation and causes cell death of human prostate cancer. In this study, the expression of CD82 gene in PC-3 cells treated with escalating concentrations of silibinin was evaluated which can result in new view for prostate cancer therapy. Materials and Methods: In this study, PC-3 cells were treated with different concentrations of silibinin for 24h. The LD50 was determined. RNA was extracted by trizol, then cDNA was synthesized. Precise primers were designed for CD82 and GAPDH genes by specific software. Quantity of CD82 gene expression compare to GAPDH gene in different concentrations of silibilin was analyzed using very sensitive quantitative Real-time PCR. Results: CD82 gene expression in PC-3 cells treated with 100, 150 and 200μg/ml of silibinin at 24h was increased by 1.97±0.26 (P<0.05), 3.00±0.26 and 3.43±0.43 (P<0.01), respectively. Conclusion: The results of quantitative Real-time PCR indicated that silibinin can probably decrease metastasis, by up-regulation of CD82 metastasis suppressor gene in PC-3 cells.
Full-Text [PDF 2327 kb]   (5706 Downloads)    

Received: 2010/05/23 | Accepted: 2010/07/28

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.